Increasing evidences have been shown that targeting PTEN and PI3K/AKT signaling pathway can inhibit or enhance chemosensitivity of several cancer types, including prostate cancer [24, 38, 39]. This evidence concerns the gene AKT1 and prostate carcinoma.